MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Clinical Lymphoma Myeloma & Leukemia
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

503 results · 1 filter active ·
Results by year
20102025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
503 works in the cohort · of 4,299,418page 7 of 11

Labels cover 1 of 503 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 503 of 503 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Poster: MM-233 Evaluation of the Comparative Effectiveness of In-Class Transition (iCT) to ALL-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) After Bortezomib (V)-Based Induction Therapy vs Patients Who Continued to Receive Parenteral V-Based Therapy in Newly Diagnosed Multiple Myeloma (NDMM)
Suman Kambhampati, Robert M. Rifkin, Caitlin Costello, Ruemu Birhiray, Joshua Richter, Rafat Abonour +8 more
2022· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Vânia Hungria, Paweł Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Wård +14 more
2024· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Poster: ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) –Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study
Julio C. Chávez, Jean‐Marie Michot, Cecilia Carpio, Silvia Martina Ferrari, Tatyana Feldman, Daniel Morillo +13 more
2022· article· en· Clinical Lymphoma Myeloma & Leukemia· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About